CoChat
Sign Up
Cited by 27Traumatic Brain Injury and Neurovascular DisturbancesTraumatic Brain Injury ResearchAutomotive and Human Injury Biomechanics

The DOI matches its Crossref record.

Biomarkers in Moderate to Severe Pediatric Traumatic Brain Injury: A Review of the Literature

Open access
Munoz Pareja, Jennifer C., Li, Xue, Gandham, Nithya, Wang, Kevin K., Lautenslager, Lauren, Pareja, Maria Camila, Shanmugham, Prashanth, Faulkinberry, Shannon, Ghosh, Suman, Kerrigan, Maria, Kashyap, Madhuri R.·2022·Pediatric Neurology
DOI 10.1016/j.pediatrneurol.2022.03.002PMC PMC9038667
Open this paper in CoChat — free account

Abstract

Background Despite decades of research, outcomes in pediatric traumatic brain injury (pTBI) remain highly variable. Brain biofluid-specific biomarkers from pTBI patients may allow us to diagnose and prognosticate earlier and with a greater degree of accuracy than conventional methods. This manuscript reviews the evidence surrounding current brain-specific biomarkers in pTBI and assesses the temporal relationship between the natural history of the traumatic brain injury (TBI) and measured biomarker levels. Methods A literature search was conducted in the Ovid, PubMed, MEDLINE, and Cochrane databases seeking relevant publications. The study selection and screening process were documented in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram. Extraction forms included developmental stages of patients, type and biofluid source of biomarkers, brain injury type, and other relevant data. Results The search strategy identified 443 articles, of which 150 examining the biomarkers of our interest were included. The references retrieved were examined thoroughly and discussed at length with a pediatric neurocritical care intensivist specializing in pTBI and a Ph.D. scientist with a high degree of involvement in TBI biomarker research, authoring a vast amount of literature in this field. Conclusions TBI biomarkers might serve as valuable tools in the diagnosis and prognosis of pTBI. However, while each biomarker has its advantages, they are not without limitations, and therefore, further research is critical in pTBI biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.pediatrneurol.2022.03.002

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 74

  1. Binder, 2005, The public health approach to traumatic brain injury: an overview of CDC's research and programs, J Head Trauma Rehabil, 20, 189, 10.1097/00001199-200505000-00002 · DOI
  2. Tabor, 2015, Food and Drug Administration requirements for clinical studies in pediatric patients, Ther Innov Regul Sci, 49, 666, 10.1177/2168479015596021 · DOI
  3. Langlois, 2005, Traumatic brain injury in the United States: research and programs of the Centers for Disease Control and Prevention (CDC), J Head Trauma Rehabil, 20, 187, 10.1097/00001199-200505000-00001 · DOI
  4. Thelin, 2017, Monitoring the neuroinflammatory response following acute brain injury, Front Neurol, 8, 351, 10.3389/fneur.2017.00351 · DOI
  5. Teasdale, 1974, Assessment of coma and impaired consciousness. A practical scale, Lancet, 2, 81, 10.1016/S0140-6736(74)91639-0 · DOI · Paper page
  6. Balestreri, 2004, Predictive value of Glasgow Coma Scale after brain trauma: change in trend over the past ten years, J Neurol Neurosurg Psychiatry, 75, 161
  7. Bigler, 2016, Structural neuroimaging findings in mild traumatic brain injury, Sports Med Arthrosc Rev, 24, e42, 10.1097/JSA.0000000000000119 · DOI
  8. Oris, 2018, The biomarker S100B and mild traumatic brain injury: a meta-analysis, Pediatrics, 141, 10.1542/peds.2018-0037 · DOI
  9. Dennis, 2021, Challenges and opportunities for neuroimaging in young patients with traumatic brain injury: a coordinated effort towards advancing discovery from the ENIGMA pediatric moderate/severe TBI group, Brain Imaging Behav, 15, 555, 10.1007/s11682-020-00363-x · DOI
  10. Kochanek, 2019, Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the brain trauma foundation guidelines, executive summary, Neurosurgery, 84, 1169, 10.1093/neuros/nyz051 · DOI
  11. Sandler, 2010, Clinical applications of biomarkers in pediatric traumatic brain injury, Childs Nerv Syst, 26, 205, 10.1007/s00381-009-1009-1 · DOI
  12. Daoud, 2014, Brain injury biomarkers as outcome predictors in pediatric severe traumatic brain injury, Neurocrit Care, 20, 427, 10.1007/s12028-013-9879-1 · DOI
  13. Sugimoto, 2015, Cardiac biomarkers in children with congenital heart disease, World J Pediatr, 11, 309, 10.1007/s12519-015-0039-x · DOI
  14. Leeb, 2015, Elevated transaminases are common in children on prophylactic treatment for tuberculosis, Acta Paediatr, 104, 479, 10.1111/apa.12908 · DOI
  15. Hicks, 2018, Overlapping MicroRNA expression in saliva and cerebrospinal fluid accurately Identifies pediatric traumatic brain injury, J Neurotrauma, 35, 64, 10.1089/neu.2017.5111 · DOI
  16. Wang, 2018, An update on diagnostic and prognostic biomarkers for traumatic brain injury, Expert Rev Mol Diagn, 18, 165, 10.1080/14737159.2018.1428089 · DOI
  17. Park, 2019, Serial measurement of S100B and NSE in pediatric traumatic brain injury, Childs Nerv Syst, 35, 343, 10.1007/s00381-018-3955-y · DOI
  18. Berger, 2002, Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children, Pediatrics, 109, E31, 10.1542/peds.109.2.e31 · DOI
  19. Berger, 2007, Serum biomarker concentrations and outcome after pediatric traumatic brain injury, J Neurotrauma, 24, 1793, 10.1089/neu.2007.0316 · DOI
  20. Pelinka, 2005, Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings, Shock, 24, 119, 10.1097/01.shk.0000168876.68154.43 · DOI
  21. Verfaillie, 2010, Hemolysis correction factor in the measurement of serum neuron-specific enolase, Clin Chem Lab Med, 48, 891, 10.1515/CCLM.2010.159 · DOI
  22. Ramont, 2005, Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice, Clin Chem Lab Med, 43, 1215, 10.1515/CCLM.2005.210 · DOI
  23. Thelin, 2017, Serial sampling of serum protein biomarkers for monitoring human traumatic brain injury dynamics: a systematic review, Front Neurol, 8, 300, 10.3389/fneur.2017.00300 · DOI
  24. Mondello, 2012, Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury, Neurosurgery, 70, 666
  25. Metzger, 2018, Temporal response profiles of serum ubiquitin C-terminal hydrolase-L1 and the 145-kDa alpha II-spectrin breakdown product after severe traumatic brain injury in children, J Neurosurg Pediatr, 22, 369, 10.3171/2018.4.PEDS17593 · DOI
  26. Berger, 2012, Serum concentrations of ubiquitin C-terminal hydrolase-L1 and αII-spectrin breakdown product 145 kDa correlate with outcome after pediatric TBI, J Neurotrauma, 29, 162, 10.1089/neu.2011.1989 · DOI
  27. Mondello, 2016, Serum concentrations of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein after pediatric traumatic brain injury, Sci Rep, 6, 28203, 10.1038/srep28203 · DOI · Paper page
  28. Ferguson, 2011, Neuronal biomarkers may require age-adjusted norms, Ann Emerg Med, 58, 213, 10.1016/j.annemergmed.2011.06.133 · DOI
  29. Rhine, 2016, Are UCH-L1 and GFAP promising biomarkers for children with mild traumatic brain injury?, Brain Inj, 30, 1231, 10.1080/02699052.2016.1178396 · DOI
  30. Simon-Pimmel, 2015, Serum S100β neuroprotein reduces use of cranial computed tomography in children after minor head trauma, Shock, 44, 410, 10.1097/SHK.0000000000000442 · DOI
  31. Babcock, 2012, Ability of S100B to predict severity and cranial CT results in children with TBI, Brain Inj, 26, 1372, 10.3109/02699052.2012.694565 · DOI
  32. Berger, 2002, Serum S100B concentrations are increased after closed head injury in children: a preliminary study, J Neurotrauma, 19, 1405, 10.1089/089771502320914633 · DOI
  33. Wilkinson, 2016, Serum biomarkers help predict attention problems in critically ill children with traumatic brain injury, Pediatr Crit Care Med, 17, 638, 10.1097/PCC.0000000000000752 · DOI
  34. Park, 2018, Prognostic value of serum levels of S100 calcium-binding protein B, neuron-specific enolase, and interleukin-6 in pediatric patients with traumatic brain injury, World Neurosurg, 118, e534, 10.1016/j.wneu.2018.06.234 · DOI
  35. Anderson, 2001, High serum S100B levels for trauma patients without head injuries, Neurosurgery, 48, 1255
  36. Bechtel, 2009, Relationship of serum S100B levels and intracranial injury in children with closed head trauma, Pediatrics, 124, e697, 10.1542/peds.2008-1493 · DOI
  37. Portela, 2002, The serum S100B concentration is age dependent, Clin Chem, 48, 950, 10.1093/clinchem/48.6.950 · DOI
  38. Undén, 2005, Raised serum S100B levels after acute bone fractures without cerebral injury, J Trauma, 58, 59
  39. Bouvier, 2011, Reference ranges for serum S100B protein during the first three years of life, Clin Biochem, 44, 927, 10.1016/j.clinbiochem.2011.05.004 · DOI
  40. Shore, 2007, Cerebrospinal fluid biomarkers versus glasgow coma scale and glasgow outcome scale in pediatric traumatic brain injury: the role of young age and inflicted injury, J Neurotrauma, 24, 75, 10.1089/neu.2006.0062 · DOI
  41. Luoto, 2017, A systematic review of the usefulness of glial fibrillary acidic protein for predicting acute intracranial lesions following head trauma, Front Neurol, 8, 652, 10.3389/fneur.2017.00652 · DOI
  42. Wang, 2016, Plasma anti-glial fibrillary acidic protein autoantibody levels during the acute and chronic phases of traumatic brain injury: a transforming research and clinical knowledge in traumatic brain injury Pilot study, J Neurotrauma, 33, 1270, 10.1089/neu.2015.3881 · DOI
  43. Papa, 2016, In children and youth with mild and moderate traumatic brain injury, glial fibrillary acidic protein out-performs S100β in detecting traumatic intracranial lesions on computed tomography, J Neurotrauma, 33, 58, 10.1089/neu.2015.3869 · DOI
  44. Fraser, 2011, Severe traumatic brain injury in children elevates glial fibrillary acidic protein in cerebrospinal fluid and serum, Pediatr Crit Care Med, 12, 319, 10.1097/PCC.0b013e3181e8b32d · DOI
  45. Gill, 2017, Acute plasma tau relates to prolonged return to play after concussion, Neurology, 88, 595, 10.1212/WNL.0000000000003587 · DOI
  46. Zemlan, 2002, C-tau biomarker of neuronal damage in severe brain injured patients: association with elevated intracranial pressure and clinical outcome, Brain Res, 947, 131, 10.1016/S0006-8993(02)02920-7 · DOI
  47. Stukas, 2019, Characterisation of serum total tau following paediatric traumatic brain injury: a case-control study, Lancet Child Adolesc Health, 3, 558, 10.1016/S2352-4642(19)30194-4 · DOI
  48. Korley, 2016, Circulating brain-derived neurotrophic factor has diagnostic and prognostic value in traumatic brain injury, J Neurotrauma, 33, 215, 10.1089/neu.2015.3949 · DOI
  49. Buonora, 2015, Multivariate analysis of traumatic brain injury: development of an assessment score, Front Neurol, 6, 68, 10.3389/fneur.2015.00068 · DOI
  50. Di Battista, 2015, Blood biomarkers in moderate-to-severe traumatic brain injury: potential utility of a multi-marker approach in characterizing outcome, Front Neurol, 6, 110, 10.3389/fneur.2015.00110 · DOI
  51. Chiaretti, 2003, Correlation between neurotrophic factor expression and outcome of children with severe traumatic brain injury, Intensive Care Med, 29, 1329, 10.1007/s00134-003-1852-6 · DOI
  52. Chiaretti, 2008, Nerve growth factor expression correlates with severity and outcome of traumatic brain injury in children, Eur J Paediatr Neurol, 12, 195, 10.1016/j.ejpn.2007.07.016 · DOI
  53. Su, 2012, Increased CSF concentrations of myelin basic protein after TBI in infants and children: absence of significant effect of therapeutic hypothermia, Neurocrit Care, 17, 401, 10.1007/s12028-012-9767-0 · DOI
  54. Berger, 2006, Serum biomarkers after traumatic and hypoxemic brain injuries: insight into the biochemical response of the pediatric brain to inflicted brain injury, Dev Neurosci, 28, 327, 10.1159/000094158 · DOI
  55. Beers, 2007, Neurocognitive outcome and serum biomarkers in inflicted versus non-inflicted traumatic brain injury in young children, J Neurotrauma, 24, 97, 10.1089/neu.2006.0055 · DOI
  56. Berger, 2006, Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool, Pediatrics, 117, 325, 10.1542/peds.2005-0711 · DOI
  57. Berger, 2010, Trajectory analysis of serum biomarker concentrations facilitates outcome prediction after pediatric traumatic and hypoxemic brain injury, Dev Neurosci, 32, 396, 10.1159/000316803 · DOI
  58. Khalil, 2018, Neurofilaments as biomarkers in neurological disorders, Nat Rev Neurol, 14, 577, 10.1038/s41582-018-0058-z · DOI · Paper page
  59. Oliver, 2016, Serum neurofilament light in American football athletes over the course of a season, J Neurotrauma, 33, 1784, 10.1089/neu.2015.4295 · DOI
  60. Martínez-Morillo, 2015, Neurofilament medium polypeptide (NFM) protein concentration is increased in CSF and serum samples from patients with brain injury, Clin Chem Lab Med, 53, 1575, 10.1515/cclm-2014-0908 · DOI
  61. Žurek, 2012, The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury, Acta Neurochir (Wien), 154, 93, 10.1007/s00701-011-1175-2 · DOI
  62. McKnight, 2014, Beclin 1 is required for neuron viability and regulates endosome pathways via the UVRAG-VPS34 complex, PLoS Genet, 10, 10.1371/journal.pgen.1004626 · DOI
  63. Kumar, 2016, Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury, Brain Behav Immun, 53, 183, 10.1016/j.bbi.2015.12.008 · DOI
  64. Kumar, 2015, Acute CSF interleukin-6 trajectories after TBI: associations with neuroinflammation, polytrauma, and outcome, Brain Behav Immun, 45, 253, 10.1016/j.bbi.2014.12.021 · DOI
  65. Crichton, 2021, Interleukin-8 predicts fatigue at 12 months post-injury in children with traumatic brain injury, J Neurotrauma, 38, 1151, 10.1089/neu.2018.6083 · DOI
  66. Nakae, 2016, Time course of coagulation and fibrinolytic parameters in patients with traumatic brain injury, J Neurotrauma, 33, 688, 10.1089/neu.2015.4039 · DOI
  67. DeFazio, 2014, The potential utility of blood-derived biochemical markers as indicators of early clinical trends following severe traumatic brain injury, World Neurosurg, 81, 151, 10.1016/j.wneu.2013.01.015 · DOI
  68. Stein, 2004, Coagulopathy in traumatic brain injury, Neurocrit Care, 1, 479, 10.1385/NCC:1:4:479 · DOI
  69. Swanson, 2010, Low plasma D-dimer concentration predicts the absence of traumatic brain injury in children, J Trauma, 68, 1072
  70. Luo, 2019, Comparison of admission serum albumin and hemoglobin as predictors of outcome in children with moderate to severe traumatic brain injury: a retrospective study, Medicine (Baltimore), 98, 10.1097/MD.0000000000017806 · DOI
  71. Gao, 2020, Plasma osteopontin may predict neuroinflammation and the severity of pediatric traumatic brain injury, J Cereb Blood Flow Metab, 40, 35, 10.1177/0271678X19836412 · DOI
  72. Nam, 2014, Global analyses of the effect of different cellular contexts on microRNA targeting, Mol Cell, 53, 1031, 10.1016/j.molcel.2014.02.013 · DOI
  73. Atif, 2019, A review of MicroRNA biomarkers in traumatic brain injury, J Exp Neurosci, 13
  74. Walko, 2014, Cerebrospinal fluid mitochondrial DNA: a novel DAMP in pediatric traumatic brain injury, Shock, 41, 499, 10.1097/SHK.0000000000000160 · DOI

Cited by

Sorted by citations

See all 27

Metadata

Authors
Munoz Pareja, J. C., Li, X., Gandham, N., Wang, K. K., Lautenslager, L., Pareja, M. C., Shanmugham, P., Faulkinberry, S., Ghosh, S., Kerrigan, M., & Kashyap, M. R.
Affiliations
  • University of Florida Health (US)
  • University of Florida (US)
ORCID
Venue
Pediatric Neurology
Publisher
Elsevier BV
Published
2022-05
Volume
130
Pages
60-68
ISSN
0887-8994 (ISSN-L)
DOI
10.1016/j.pediatrneurol.2022.03.002
PMC
PMC9038667
OpenAlex
W4220906708
Cited by
27
References
0
Citations by year
2026: 6 · 2025: 11 · 2024: 6 · 2023: 4
FWCI
0.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Pediatric Neurology (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Neurological Disorders and Stroke (U01NS086090)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury and Neurovascular Disturbances
  • Health Sciences › Medicine › Clinical Neurology › Traumatic Brain Injury Research
  • Physical Sciences › Engineering › Biomedical Engineering › Automotive and Human Injury Biomechanics
Keywords
pediatric traumatic brain injury, biomarkers, prognosis, diagnosis, cerebrospinal fluid, blood biomarkers, neurocritical care
MeSH terms
Brain Injuries, Traumatic, Brain, Brain Injuries, Child, Humans, Prognosis, Biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review